Although CD46 and TREM1 participate in distinct immune regulatory pathways—CD46 primarily influences the complement system and T cell function, while TREM1 enhances myeloid cell-mediated inflammatory responses—they exhibit significant synergy in jointly shaping the immunosuppressive tumor microenvironment. Here, TREM1 is linked to neoplasm.